After AbbVie's $10.9B Buyout, Apogee's Executives Return to Paragon to Scale the Engine
In a striking move for biotech's company-building model, the core leadership team of Apogee Therapeutics has decamped together to Paragon Labs, the antibody discovery shop that originally created Apogee. Paragon announced on October 13 that Michael Henderson, M.D., Apogee's former CEO, will lead Paragon Labs as chief executive. He is joined by Carl Dambkowski, M.D., as head of R&D; Dan Mulreany as chief business and financial officer; Matt Batters, J.D., as chief legal officer; and Emily Cox as chief people officer.
The move comes weeks after AbbVie closed its acquisition of Apogee on September 3, 2026, paying $135.11 per share in cash for a total equity value of roughly $10.9 billion — about a 49% premium to Apogee's June 18 close before the deal was announced, and AbbVie's largest acquisition since Allergan. AbbVie funded the purchase with debt, including a multi-tranche senior notes offering. The deal is the payoff on Apogee's late-stage eczema asset, zumilokibart.
Paragon Labs, based in Waltham, Massachusetts and founded by life-sciences investment firm Fairmount, operates as an antibody discovery and company-creation platform rather than a drug seller. Its discovered programs have anchored nine biotech companies: Apogee, Spyre, Oruka, Jade Biosciences, Crescent Biopharma, Korsana Biosciences, Mentari, Damora and, as of the same day, Velaris Therapeutics. Zumilokibart itself was originally developed inside Paragon before being licensed to Apogee.
Henderson framed the move as institutionalizing Apogee's lessons at the platform level. "At Apogee, we learned a tremendous amount about what it takes to translate Paragon-discovered programs into clinical-stage medicines," he said. "We now have an opportunity to apply those lessons to clinical development, regulatory strategy and execution from the very start... bringing all of these insights to make decisions even earlier, so the companies that license Paragon's most promising assets can bring them to patients even faster."
Before the sale, the Apogee team advanced five Paragon-discovered assets into clinical development. Its lead, zumilokibart, is a high-affinity anti-IL-13 antibody engineered for an extended half-life of roughly 77 days. In the Phase 2 APEX Part B trial, presented as a late breaker at EADV 2026 on September 30, all three dose regimens met the primary endpoint: EASI-75 response rates at week 16 were 65.9% for the mid dose, 61.6% for high dose and 50.5% for low dose, versus 23.4% on placebo, across 346 randomized participants. The mid dose advanced to Phase 3, with AbbVie expecting registrational enrollment this year and a potential launch in early 2030.
Paragon timed the leadership announcement alongside the creation of Velaris Therapeutics, its ninth company built on Paragon-discovered assets. Velaris focuses on pulmonary arterial hypertension and related cardiopulmonary diseases, with ActRII-Fc ligand traps aimed at restoring normal signaling pathways. Rather than pursuing a conventional IPO, Velaris went public through a reverse merger with Alaunos Therapeutics — a model Paragon has honed over the past four years.
Velaris is the first company supported by the expanded leadership team. Paragon said the group will both advance the clinical development of its discovered assets and form new biotech companies around promising candidates. With Apogee's $10.9 billion sale as a public validation, Paragon is effectively recycling a management team that has already been tested by a mega-cap acquisition.
The deal has not been free for AbbVie. The company cut its full-year 2026 adjusted EPS guidance from $13.91–$14.11 to $13.87–$14.07, with Apogee dilution of roughly 14 cents outweighing a 10-cent lift from the existing business, plus headwinds from acquired IPR&D and milestone expenses. In return, AbbVie gains a potential immunology franchise: about two-thirds of patients achieved significant skin clearance at 16 weeks in the Phase 2 trial, and the roughly 77-day half-life could support differentiated dosing intervals against rivals such as Dupixent.
The question now is whether the playbook repeats. Apogee's executives left behind a pipeline at AbbVie entering Phase 3, and returned to a factory that has already shipped nine companies. If the Paragon model holds, a tenth spin-out — now with clinical and regulatory judgment baked into the platform from day one — may not be far behind.